{"title":"印度尼西亚东努沙登加拉60岁糖尿病患者COVID-19再感染","authors":"Heri Sutrisno Prijopranoto, Albert William Hotomo","doi":"10.54730/abm.2021.030601","DOIUrl":null,"url":null,"abstract":"Coronavirus Disease 2019 (COVID-19) is an infectious disease which is caused by a new strain of coronavirus. Older individuals and people with comorbidities have a higher risk to develop more severe illness. COVID-19 survivors will have active immunity in conjunction with increase of SARS-CoV-2 antibody (Ab) titer 2-weeks after the symptoms onset and will be lasted until 12-weeks. Therefore, it will give protection against reinfection of COVID-19. This study reports a case of COVID-19 rapid reinfection in sixty-year-old man with diabetes mellitus. Case illustration: a sixty-year-old man presented to the emergency department with fever accompanied by cough, runny nose, malaise, and metallic taste since one day before admission to hospital. There was a history of uncontrolled diabetes mellitus (DM) and COVID-19 infection 35-days before hospital admission without any symptoms. The current physical examinations demonstrated a mild dyspnea with oxygen saturation 97%, and diffuse rhonchi at the right area of chest auscultation. Chest X-ray discovered a multiple consolidation of the right lung, with suspicion of viral pneumonia. Fasting blood glucose (FBG) was 205 mg/dl, and 2-hour postprandial glucose was 508 mg/dl. The polymerase chain reaction (PCR) of SARS-CoV-2 via nasopharyngeal swab was taken and the result was positive. COVID-19 Ab titers IgM and IgG were 0.18 U/ml and 0.43 U/ml (<0.8 U/ml → non-reactive), respectively. The patient was diagnosed with COVID-19 reinfection and DM. The patient was treated with convalescent plasma, antivirus, antibiotics, insulin, steroid, anticoagulant, and other symptomatic medications. As the results, a well improvement of his clinical condition and the increase of Ab COVID-19 IgM and IgG evaluation test after convalescent plasma administration, 0.28 AU/ml and 17.67 AU/ml, respectively, were recorded. Summary: Researches revealed that DM might cause the specific immunity system dysfunction and the low production of antibody. This study found that poor blood-glucose control with a low Ab of SARS-CoV-2 production might induce this patient to have a COVID-19 reinfection. Advance immunological study about the correlation between DM and COVID-19 is very essential in the management of COVID-19 patients with DM.","PeriodicalId":7179,"journal":{"name":"Advanced Biomedicine","volume":"61 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"COVID-19 Reinfection in 60-Year-Old Man with Diabetes Mellitus, East Nusa Tenggara, Indonesia\",\"authors\":\"Heri Sutrisno Prijopranoto, Albert William Hotomo\",\"doi\":\"10.54730/abm.2021.030601\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Coronavirus Disease 2019 (COVID-19) is an infectious disease which is caused by a new strain of coronavirus. Older individuals and people with comorbidities have a higher risk to develop more severe illness. COVID-19 survivors will have active immunity in conjunction with increase of SARS-CoV-2 antibody (Ab) titer 2-weeks after the symptoms onset and will be lasted until 12-weeks. Therefore, it will give protection against reinfection of COVID-19. This study reports a case of COVID-19 rapid reinfection in sixty-year-old man with diabetes mellitus. Case illustration: a sixty-year-old man presented to the emergency department with fever accompanied by cough, runny nose, malaise, and metallic taste since one day before admission to hospital. There was a history of uncontrolled diabetes mellitus (DM) and COVID-19 infection 35-days before hospital admission without any symptoms. The current physical examinations demonstrated a mild dyspnea with oxygen saturation 97%, and diffuse rhonchi at the right area of chest auscultation. Chest X-ray discovered a multiple consolidation of the right lung, with suspicion of viral pneumonia. Fasting blood glucose (FBG) was 205 mg/dl, and 2-hour postprandial glucose was 508 mg/dl. The polymerase chain reaction (PCR) of SARS-CoV-2 via nasopharyngeal swab was taken and the result was positive. COVID-19 Ab titers IgM and IgG were 0.18 U/ml and 0.43 U/ml (<0.8 U/ml → non-reactive), respectively. The patient was diagnosed with COVID-19 reinfection and DM. The patient was treated with convalescent plasma, antivirus, antibiotics, insulin, steroid, anticoagulant, and other symptomatic medications. As the results, a well improvement of his clinical condition and the increase of Ab COVID-19 IgM and IgG evaluation test after convalescent plasma administration, 0.28 AU/ml and 17.67 AU/ml, respectively, were recorded. Summary: Researches revealed that DM might cause the specific immunity system dysfunction and the low production of antibody. This study found that poor blood-glucose control with a low Ab of SARS-CoV-2 production might induce this patient to have a COVID-19 reinfection. Advance immunological study about the correlation between DM and COVID-19 is very essential in the management of COVID-19 patients with DM.\",\"PeriodicalId\":7179,\"journal\":{\"name\":\"Advanced Biomedicine\",\"volume\":\"61 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-12-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advanced Biomedicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.54730/abm.2021.030601\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced Biomedicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.54730/abm.2021.030601","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
2019冠状病毒病(COVID-19)是一种由新型冠状病毒引起的传染病。老年人和患有并发症风险较高发展更严重的疾病。COVID-19幸存者在症状出现2周后将具有主动免疫,同时SARS-CoV-2抗体(Ab)滴度增加,并将持续到12周。因此,它将提供防止COVID-19再次感染的保护。本研究报告1例60岁男性糖尿病患者COVID-19快速再感染。病例说明:一名六十岁男性,入院前一日以发热伴咳嗽、流鼻水、不适及金属味就诊于急诊科。入院前35 d有糖尿病(DM)和COVID-19感染未控制史,无症状。目前的体格检查显示轻度呼吸困难,氧饱和度97%,胸部听诊右侧弥漫性隆气。胸部x光发现了多个合并肺,病毒性肺炎的怀疑。空腹血糖(FBG) 205 mg/dl,餐后2小时血糖508 mg/dl。采用鼻咽拭子对SARS-CoV-2进行聚合酶链反应(PCR)检测,结果为阳性。COVID-19 Ab浓度IgM和免疫球蛋白0.18 U /毫升和0.43 U /毫升(< 0.8 U /毫升→无电抗),分别。病人被诊断为COVID-19再感染和DM病人康复的等离子体处理,抗病毒、抗生素、胰岛素,类固醇,抗凝和其他症状的药物。作为结果,改善他的临床条件和Ab COVID-19 IgM的增加和免疫球蛋白鉴定试验后恢复期的等离子体管理、0.28 AU /毫升和17.67 AU / ml,分别记录。摘要:研究表明,糖尿病可能导致特异性免疫系统功能障碍和抗体产生低下。本研究发现,血糖控制不佳且SARS-CoV-2产生的Ab值较低可能导致该患者再次感染COVID-19。糖尿病和COVID-19推进免疫学研究之间的关系是非常重要的在COVID-19 DM患者的管理。
COVID-19 Reinfection in 60-Year-Old Man with Diabetes Mellitus, East Nusa Tenggara, Indonesia
Coronavirus Disease 2019 (COVID-19) is an infectious disease which is caused by a new strain of coronavirus. Older individuals and people with comorbidities have a higher risk to develop more severe illness. COVID-19 survivors will have active immunity in conjunction with increase of SARS-CoV-2 antibody (Ab) titer 2-weeks after the symptoms onset and will be lasted until 12-weeks. Therefore, it will give protection against reinfection of COVID-19. This study reports a case of COVID-19 rapid reinfection in sixty-year-old man with diabetes mellitus. Case illustration: a sixty-year-old man presented to the emergency department with fever accompanied by cough, runny nose, malaise, and metallic taste since one day before admission to hospital. There was a history of uncontrolled diabetes mellitus (DM) and COVID-19 infection 35-days before hospital admission without any symptoms. The current physical examinations demonstrated a mild dyspnea with oxygen saturation 97%, and diffuse rhonchi at the right area of chest auscultation. Chest X-ray discovered a multiple consolidation of the right lung, with suspicion of viral pneumonia. Fasting blood glucose (FBG) was 205 mg/dl, and 2-hour postprandial glucose was 508 mg/dl. The polymerase chain reaction (PCR) of SARS-CoV-2 via nasopharyngeal swab was taken and the result was positive. COVID-19 Ab titers IgM and IgG were 0.18 U/ml and 0.43 U/ml (<0.8 U/ml → non-reactive), respectively. The patient was diagnosed with COVID-19 reinfection and DM. The patient was treated with convalescent plasma, antivirus, antibiotics, insulin, steroid, anticoagulant, and other symptomatic medications. As the results, a well improvement of his clinical condition and the increase of Ab COVID-19 IgM and IgG evaluation test after convalescent plasma administration, 0.28 AU/ml and 17.67 AU/ml, respectively, were recorded. Summary: Researches revealed that DM might cause the specific immunity system dysfunction and the low production of antibody. This study found that poor blood-glucose control with a low Ab of SARS-CoV-2 production might induce this patient to have a COVID-19 reinfection. Advance immunological study about the correlation between DM and COVID-19 is very essential in the management of COVID-19 patients with DM.